September 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
2
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
3
Silevertinib CNS Activity Supports Planned Phase 3 in EGFR-Mutant NSCLC
4
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
5
